

Iowa Medicaid Drug Utilization Review (DUR) Commission

February 7, 2024

Location[†]: **VIRTUAL ONLY**
Meeting format has changed to virtual only.

Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m6fc37adab59de12c064f877e96c4da17>

Dial In: 1-844-621-3956

Meeting Number: 2537 233 7543

Meeting Password: auTpqscU343

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the November 1, 2023 Meeting Minutes
 - b) November 2023 DUR Recommendation Letter to DHHS
 - c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Wellpoint Iowa (formerly known as Amerigroup Iowa)
 - b) Fee for Service
 - c) Molina Healthcare of Iowa
 - d) Iowa Total Care
 - e) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal – **Registration required**. A complete conflict of disclosure form is required for all public comment and must be submitted at time of registration. Five (5) minute maximum limit.
 - Written – Must submit written comments and a completed conflict of interest disclosure.
 - **Submissions must be received no later than 4:30 p.m. CT January 31, 2024.**
 - Indicate in email if providing written or verbal comment. Send to info@iadur.org
 - Reference complete public comment policy [here](#).
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Antidepressants in Children
 1. Utilization by Age Band
 2. Duplicate Therapy

3. Trazodone Dose
 - ii. Mood Stabilizers in Children
 - iii. Low Dose Quetiapine in Children
- b) Proposal(s)
 - i. Diagnosis of Diabetes Mellitus without Statin Therapy
 - ii. Concurrent use of Levetiracetam and Clobazam
- c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization
 - a) Biologicals for Arthritis – Initial Review
 - b) Biologicals for Hidradenitis Suppurativa – Initial Review
 - c) Dupilumab (Dupixent) – Initial Review
 - d) Febuxostat (Uloric) – Removal of Criteria – Initial Review
 - e) Select Preventative Migraine Treatments – Initial Review
 - f) Hepatitis C Treatment, Direct Acting Antivirals - Initial Review
 - g) Odevixibat (Bylvay) - Second Review
 - h) Oral Constipation Agents – Second Review
 - i) Oral Immunotherapy – Second Review
 - j) Vesicular Monoamine Transporter (VMAT) 2 Inhibitors – Second Review
9. Miscellaneous
 - a) DUR Digest Vol. 36, No. 1 – Second Review

10. MedWatch

[FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam \(Keppra, Keppra XR, Elepsia XR, Spritam\) and clobazam \(Onfi, Sympazan\)](#)

[Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict-of-interest disclosure form late will have their request to speak denied or will not have their comments shared.

‡ Always check the DUR website for updates regarding meeting format, as this can change after the agenda is initially posted.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131.

Next Meeting
May 1, 2024
Location: TBD